Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company based in Atlanta, GA. They are dedicated to developing innovative treatments and cures for Alzheimer's disease, Bipolar disorder, Major Depressive Disorder (MDD), and Post-Traumatic Stress Disorder (PTSD). With a mission to provide relief to the millions of Americans suffering from these debilitating diseases, Alzamend Neuro focuses on rapidly developing and bringing safe and effective therapies to the market. Their current pipeline includes two promising drug candidates, AL001 and ALZN002, which aim to address the specific needs of patients through novel therapeutic approaches.
AL001, a patented ionic cocrystal technology, delivers lithium in combination with proline and salicylate to provide a next-generation therapeutic drug candidate. ALZN002, on the other hand, utilizes a patented method that employs a mutant-peptide sensitized cell as a cell-based therapeutic vaccine. This approach seeks to restore the patient's immunological system's ability to combat Alzheimer's disease. Both drug candidates are licensed from the University of South Florida Research Foundation, Inc. under exclusive worldwide licenses. Alzamend Neuro's commitment to research and innovation drives their pursuit of effective treatments for these prevalent neurological conditions.
Generated from the website